BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT
PITTSBURGH, May 25, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform...
Source: globenewswire.com
Kim Jaffe News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kim Jaffe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kim Jaffe Today - Breaking & Trending Today
BlueSphere Bio Data to be Presented at the 2022 American
PITTSBURGH, March 15, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery...
Source: globenewswire.com
BlueSphere Bio to Present at the BIO CEO & Investor
PITTSBURGH, Feb. 08, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery...
Source: globenewswire.com
OncoSec Medical Announces Proposed Public Offering of Common Stock
Press release content from PR Newswire. The AP news staff was not involved in its creation. OncoSec Medical Announces Proposed Public Offering of Common Stock January 20, 2021 GMT OncoSec Medical Incorporated logo (PRNewsfoto/OncoSec Medical Incorporated) PENNINGTON, N.J. and SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response ...
Source: apnews.com
OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™
Share this article Share this article PENNINGTON, N.J. and SAN DIEGO, Jan. 19, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Company's lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends to capitalize on both the extensive experience Sirtex has in marketing drug/device combination pro...
Source: prnewswire.com